Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | B2M del |
Therapy | GVAX + unspecified PD-1 antibody |
Indication/Tumor Type | melanoma |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
B2M del | melanoma | resistant | GVAX + unspecified PD-1 antibody | Preclinical | Actionable | In a preclinical study, GVAX in combination with an anti-PD1 treatment did not inhibit tumor growth or increase survival in a syngeneic mouse model of melanoma harboring B2M deletion (PMID: 30559380). | 30559380 |
PubMed Id | Reference Title | Details |
---|---|---|
(30559380) | Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. | Full reference... |